Hopeful News For Peritoneal Mesothelioma Drug, Apitolisib

Peritoneal is a rarer form of mesothelioma accounting for about 20% of the total diagnoses of the asbestos caused cancer. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen. British researchers published a study in ESMO Open showing promising results especially when used to treat relapse.

According to the National Cancer Institute, the one year survival rate for peritoneal mesothelioma is 40%. The British study details two cases of peritoneal mesothelioma where the patients were treated apitolsib and are still alive after 10 and 13 years. The two female patients both had relapsed under the standard chemotherapy with cisplatin treatment protocol before being treated with the apitolsib.

Apitolsib operates by inhibiting important cell signaling pathways making it harder for certain kinds of mesothelioma tumors to grow unchecked. Lead author of the study, Saoirse Dolly wrote, “These case presentations highlight a subgroup of rare MPeM that behave indolently that is compatible with long-term survival. This series identifies the use of targeted therapies with PI3K-mTOR-based inhibitors as a novel approach, warranting further clinical assessment.”

The researchers are hopeful that these preliminary results will encourage more early phase clinical trials to confirm the efficacy of the new drug treatment.

The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.

Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers